Voglibose

Voglibose

Clinical data
ATC code	A10BF03 (WHO)
Identifiers
IUPAC name (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)- 1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
CAS Number	83480-29-9
PubChem CID	444020
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H21NO7
Molar mass	267.28 g/mol

WikiDoc Resources for Voglibose
Articles
Most recent articles on Voglibose Most cited articles on Voglibose Review articles on Voglibose Articles on Voglibose in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Voglibose Images of Voglibose Photos of Voglibose Podcasts & MP3s on Voglibose Videos on Voglibose
Evidence Based Medicine
Cochrane Collaboration on Voglibose Bandolier on Voglibose TRIP on Voglibose
Clinical Trials
Ongoing Trials on Voglibose at Clinical Trials.gov Trial results on Voglibose Clinical Trials on Voglibose at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Voglibose NICE Guidance on Voglibose NHS PRODIGY Guidance FDA on Voglibose CDC on Voglibose
Books
Books on Voglibose
News
Voglibose in the news Be alerted to news on Voglibose News trends on Voglibose
Commentary
Blogs on Voglibose
Definitions
Definitions of Voglibose
Patient Resources / Community
Patient resources on Voglibose Discussion groups on Voglibose Patient Handouts on Voglibose Directions to Hospitals Treating Voglibose Risk calculators and risk factors for Voglibose
Healthcare Provider Resources
Symptoms of Voglibose Causes & Risk Factors for Voglibose Diagnostic studies for Voglibose Treatment of Voglibose
Continuing Medical Education (CME)
CME Programs on Voglibose
International
Voglibose en Espanol Voglibose en Francais
Business
Voglibose in the Marketplace Patents on Voglibose
Experimental / Informatics
List of terms related to Voglibose

Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.

Glenmark is also producing voglibose under brand name vocarb.

Diabetes is chronic metabolic disorder characterised by hyperglycemia which is due to relative or absolute deficiency of insulin or insulin resistance.

PPHG is termed as Post Prandial Hyperglycemia which is primarily due to first phase insulin secretion. Alpha glucosidase inhibitor is one agent which delays the glucose absorption at the intestine level and thereby prevents sudden surge of glucose post meal.

There are three molecules which belong to this class namely, Acarbose, Miglitol and Voglibose. Voglibose is the latest molecule in this class. Voglibose scores over both Acarbose and MIglitol in terms of potency and side effect profile.

There are several trials supporting the use of Voglibose in the management of PPHG. Also, it has been established that it is PPHG not FPG which is marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and Voglibose is indicated for the management of PPHG.

Sun Pharmaceuticals launched Voglibose 0.2 / 0.3 mg under the brand name VOLIBO.

External links

• voglibose.com
• diabetesincontrol.com
• diabetesjournals.org
• Ranbaxy announcement

Template:WikiDoc Sources